|
|
The future of oligonucleotide therapies demands a shift from unsustainable, low-yield manufacturing. Experts discuss the need for enzymatic synthesis and flexible facility design to meet growing patient needs and unlock the full potential of these treatments. |
|
|
|
Scaling oligonucleotide synthesis isn't as straightforward as it seems. Let's examine its challenges and how they can be addressed through innovative automation, intuitive software, and expert support for smoother transitions and optimized processes. |
|
|
|
This buyer's guide offers guidance on selecting appropriate equipment and components for optimal synthesis, purification, and scaling. Explore key features to consider, such as automation, synthesis speed and scalability, quality control, monitoring, and more, as well as insights into budget and vendor considerations, like initial investment, operating costs, and regulatory compliance. |
|
|
|
|
Discover cutting-edge oligonucleotide manufacturing equipment from Asahi Kasei Bioprocess, designed for precision and scalability. Our high-performance automated systems and robust synthesis columns streamline your workflow, meeting the growing demand for oligo drug substances with unparalleled accuracy and efficiency. |
|
|
|
The time between batches for oligonucleotide synthesis has long been a bottleneck, consuming valuable lab time with complex, multi-step column maintenance. A new column design can simplify this process. |
|
|
|
|
